Botulinum toxin type A in post-stroke upper limb spasticity

Current Medical Research and Opinion

Volumn 26, Issue 8, 2010, Pages 1983-1992

  Kaji, Ryuji ^a   Osako, Yuka ^b   Suyama, Kazuaki ^b   Maeda, Toshio ^b   Uechi, Yasuyuki ^b   Iwasaki, Masaru ^b  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Development and Medical Affairs Division   (Japan)

Author keywords

Botulinum toxin type A; Disability Assessment Scale; Modified Ashworth Scale; Spasticity; Upper limb

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ADULT; AGED; ARM MUSCLE; ARM SPASTICITY; ARTHRALGIA; ARTICLE; ASPIRATION; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; DAILY LIFE ACTIVITY; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; EMPHYSEMA; EPILEPSY; FALLING; FEMALE; FINGER; FLEXOR MUSCLE; FOLLOW UP; HUMAN; HUMERUS FRACTURE; INJECTION SITE CONTUSION; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE TONE; MUSCLE WEAKNESS; PERFORMANCE; PLEURA EMPYEMA; PLEURISY; POSITION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; SPASTICITY; STROKE; SUBCUTANEOUS HEMORRHAGE; SUICIDE; THERAPY EFFECT; THUMB; TIBIA FRACTURE; TREATMENT OUTCOME; WRIST;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; ARM; ASIAN CONTINENTAL ANCESTRY GROUP; BOTULINUM TOXIN TYPE A; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; STROKE; THUMB; TREATMENT OUTCOME; WRIST JOINT; YOUNG ADULT;

EID: 77954746101     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.497103     Document Type: Article

References (31)

1. Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, eds. Spasticity: Disordered Motor Control. Chicago: Year Book Medical Publishers, 1980:485-94
2. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395-400
3. Turner-Stokes L, Ward A. Guidelines for the use of botulinum toxin (BTX) in the management of spasticity in adults. London: Royal College of Physicians, 2002
4. Bogey RA, Geis CC, Bryant PR, et al. Stroke and Neurodegenerative Disorders. 3. Stroke: Rehabilitation Management. Arch Phys Med Rehabil 2004; 85(Suppl 1):S15-20
5. Ward AB. A summary of spasticity management-a treatment algorithm. Eur J Neurol 2002;9(Suppl 1):48-52
6. Childers MK, Brashear A, Jozefczyk P, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004;85:1063-9
7. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996;46:1306-10
8. Gordon MF, Brashear A, Elovic E, et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004;63: 1971-3
9. Elovic EP, Brashear A, Kaelin D, et al. Repeated treatments with botulinum toxin type A produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil 2008;89:799-806
10. Rosales RL, Chua-Yap AS. Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. J Neural Transm 2008;115:617-23
11. Simpson DM, Gracies JM, Graham HK, et al. Assessment: Botulinum neuro-toxin for the treatment of spasticity (an evidence-based review). Neurology 2008;70:1691-8
12. Elia AE, Filippini G, Calandrella D, et al. Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. Mov Disord 2009; 24:801-12
13. Bohannon RW, Smith MB. Interrater reliability of a Modified Ashworth Scale of muscle spasticity. Phys Ther 1987;67:206-7
14. Brashear A, Zafonte R, Corcoran M, et al. Inter-and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil 2002;83:1349-54
15. Brin MF. Dosing, administration, and a treatment algorithm for use of botu-linum toxin A for adult-onset spasticity. Muscle Nerve Suppl 1997;6:S208-20
16. Allergan K.K. Clinical trial of AGN191622 (Botulinum toxin A) in post-stroke upper limb spasticity. Tokyo: Allergan K.K.; 2005. Internal study report AGN191622-910
17. Matthews JNS, Altman DG, Campbell MJ, et al. Analysis of serial measurements in medical research. BMJ 1990;300:230-5
18. Liu C, A Li Wan Po, Blumhardt LD. 'Summary measure' statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:726-9
19. Pham B, Cranney A, Boers M, et al. Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials. J Rheumatol 1999;26:712-16
20. Smith SJ, Ellis E, White S, et al. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000;14:5-13
21. Turkel CC, Bowen B, Liu J, et al. Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil 2006;87:786-92
22. Simpson DM, Gracies JM, Yablon SA, et al. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry 2009;80:380-5
23. Sun SF, Hsu CW, Sun HP, et al. Combined Botulinum toxin Type A with modified constraint-induced movement therapy for chronic stroke patients with upper extremity spasticity: a randomized controlled study. Neurorehabil Neural Repair 2010;24:34-41
24. Kaji R, Osako Y, Suyama K, et al. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol 2010: published online 1 April 2010, doi:10.1007/s00415-010-5526-3
25. Anderson TJ, Rivest J, Stell R, et al. Botulinum toxin treatment of spasmodic torticollis. J R Soc Med 1992;85:524-9
26. Brin MF, Blitzer A. Botulinum toxin: dangerous terminology errors. J R Soc Med 1993;86:493-4
27. Marsden CD. Botulinum toxin: dangerous terminology errors. Reply. J R Soc Med 1993;86:494
28. Chapman MA, Barron R, Tanis DC, et al. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 2007;29:1325-37
29. Wenzel R, Jones D, Borrego JA. Comparing two botulinum toxin type A formulations using manufacturers' product summaries. J Clin Pharm Ther 2007;32:387-402
30. Harper L. Botulinum toxin A-when is a unit not a unit? J Urol 2009; 181:414-15
31. Botox® Product Information (Revised October 2006, USA)